These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 24044187)

  • 1. [Treatment with cinacalcet in secondary hyperparathyroidism for dialysis patients: The will is good--but what about the evidence?].
    Bárány P; Elinder CG; Samuelsson O
    Lakartidningen; 2013 Aug 21-Sep 3; 110(34-35):1481-3. PubMed ID: 24044187
    [No Abstract]   [Full Text] [Related]  

  • 2. A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries.
    Iannazzo S; Carsi M; Chiroli S
    Appl Health Econ Health Policy; 2012 Mar; 10(2):127-38. PubMed ID: 22268372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinacalcet hydrochloride for the treatment of hyperparathyroidism.
    Verheyen N; Pilz S; Eller K; Kienreich K; Fahrleitner-Pammer A; Pieske B; Ritz E; Tomaschitz A
    Expert Opin Pharmacother; 2013 Apr; 14(6):793-806. PubMed ID: 23452174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights into the role of calcium-sensing receptor activation.
    Cozzolino M; Mazzaferro S; Messa P
    J Nephrol; 2011; 24 Suppl 18():S38-41. PubMed ID: 21623581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cinacalcet: will it play a role in reducing cardiovascular events?
    Karohl C; Raggi P
    Future Cardiol; 2012 May; 8(3):357-70. PubMed ID: 22420327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism.
    Yousaf F; Charytan C
    Ren Fail; 2014 Feb; 36(1):131-8. PubMed ID: 24060145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of tumoral calcinosis after the appropriate control of a deranged mineral and bone metabolism, in conjugation with cinacalcet hydrochloride treatment, in a chronic hemodialysis patient.
    Yamada S; Tsuruya K; Kitazono T
    Ther Apher Dial; 2013 Jun; 17(3):348-9. PubMed ID: 23735152
    [No Abstract]   [Full Text] [Related]  

  • 8. Decrease of serum sphingosine-1-phosphate levels in hemodialysis patients with secondary hyperparathyroidism treated with cinacalcet.
    Yokoyama K; Ohkido I; Iwamoto T; Ishida M; Urashima M; Hosoya T
    Clin Nephrol; 2012 Jul; 78(1):85-6. PubMed ID: 22732343
    [No Abstract]   [Full Text] [Related]  

  • 9. Cinacalcet improves control of secondary hyperparathyroidism in peritoneal dialysis: a multicenter study.
    Portolés J; López-Sánchez P; Bajo MA; Castellano I; del Peso G; Rodríguez JR; Ribera M; Ortigosa A; Selgas R
    Perit Dial Int; 2012; 32(2):208-11. PubMed ID: 22383721
    [No Abstract]   [Full Text] [Related]  

  • 10. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utilization of cinacalcet in hypercalcemic conditions.
    Messa P; Alfieri C; Brezzi B
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):517-28. PubMed ID: 21361849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Calcimimetic drugs in stage 3-5 chronic kidney disease].
    Grzegorzewska AE; Niepolski L
    Pol Merkur Lekarski; 2012 Apr; 32(190):260-2. PubMed ID: 22708286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
    Drüeke TB
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism.
    Lien YH; Silva AL; Whittman D
    Nephrol Dial Transplant; 2005 Jun; 20(6):1232-7. PubMed ID: 15840675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of cinacalcet in treating secondary hyperparathyroidism.
    Brommage D; Gallgano C
    Nephrol Nurs J; 2005; 32(2):229-31. PubMed ID: 15889812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism.
    Komaba H; Koizumi M; Tanaka H; Takahashi H; Sawada K; Kakuta T; Fukagawa M
    Nephrol Dial Transplant; 2012 May; 27(5):1967-9. PubMed ID: 22140124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cinacalcet may prolong the QT interval in patients on haemodialysis with secondary hyperparathyroidism.
    Borrego-Utiel FJ; Pérez-del Barrio Mdel P; Biechy-Baldan Mdel M; Segura-Torres P
    Nefrologia; 2013; 33(2):272-3. PubMed ID: 23511764
    [No Abstract]   [Full Text] [Related]  

  • 18. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cinacalcet: new drug. Secondary hyperparathyroidism: where are the clinical data?
    Prescrire Int; 2006 Jun; 15(83):90-3. PubMed ID: 16764095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan.
    Komaba H; Moriwaki K; Goto S; Yamada S; Taniguchi M; Kakuta T; Kamae I; Fukagawa M
    Am J Kidney Dis; 2012 Aug; 60(2):262-71. PubMed ID: 22445709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.